BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

Boehringer Ingelheim Animal Health USA Inc. is the U.S. animal health division of the global, family-owned pharmaceutical company Boehringer Ingelheim. The company's core business is dedicated to the research, development, manufacturing, and marketing of innovative animal health products. Its mission is to enhance the well-being of both animals and humans by preventing disease, championing innovation, and fostering the bond between people and animals. The U.S. Animal Health headquarters is located in Duluth, Georgia.

The company offers a comprehensive portfolio of vaccines, parasite-control products, and therapeutics for various market segments, including companion animals (pets and horses) and livestock (cattle, poultry, and swine). Key products include well-known brands such as NexGard, Heartgard Plus, and Frontline. Beyond pharmaceutical products, Boehringer Ingelheim Animal Health USA Inc. also provides services like online order management, rebate programs, and professional training resources for veterinarians.

As the second-largest animal health business globally, Boehringer Ingelheim Animal Health holds a leading position in parasiticides and vaccines worldwide. Randolph Legg serves as the U.S. President of Animal Health, appointed in January 2021, and Dr. Scott King was named Executive Director of the U.S. cattle business in March 2023. The parent company, Boehringer Ingelheim, acquired Saiba Animal Health AG in September 2024 to bolster its R&D capabilities in pet therapeutics and plans to invest approximately $20 billion in its U.S. human and animal health businesses between 2025 and 2030, with a significant portion allocated to R&D. Additionally, in 2025, the company initiated a strategic digital health collaboration with Eko Health to enhance the early detection of heart disease in dogs.

Latest updates

Boehringer Ingelheim Leverages Braves Partnership to Boost Animal Health Visibility

Event summary

  • Boehringer Ingelheim and the Atlanta Braves have revived 'The Dogout,' an in-stadium celebration honoring veterinary professionals and their dogs.
  • The initiative is linked to Boehringer Ingelheim's 'Going Beyond' global marketing campaign.
  • A commemorative bobblehead featuring Braves player Michael Harris II and his dog, Cash, will be distributed on May 13th.
  • Boehringer Ingelheim will donate to the Ozzie Albies Foundation to support local animal shelters.

The big picture

Boehringer Ingelheim’s partnership with the Atlanta Braves represents a strategic effort to enhance brand visibility and loyalty within the animal health market. The 'Dogout' initiative leverages the Braves' regional popularity and community engagement to extend Boehringer's 'Going Beyond' campaign, which emphasizes the company’s commitment to animal wellbeing. This type of experiential marketing is increasingly common as companies seek to differentiate themselves in a crowded market and build deeper connections with consumers.

What we're watching

Brand Resonance
The success of this campaign hinges on whether the Braves partnership genuinely resonates with Boehringer Ingelheim’s target audience of veterinarians and pet owners, and whether it translates to measurable brand lift.
Campaign ROI
Boehringer Ingelheim will need to carefully track the return on investment for this sponsorship, considering the cost of the bobblehead promotion, on-field presentation, and overall campaign execution.
Competitive Response
Other animal health companies may seek similar partnerships with sports teams to gain market share, potentially intensifying competition for veterinarian and consumer attention.
CID: 2852